Literature DB >> 33925518

Understanding the Challenges and Uncertainties of Seroprevalence Studies for SARS-CoV-2.

David McConnell1,2, Conor Hickey1,2, Norma Bargary3, Lea Trela-Larsen1,2, Cathal Walsh1,3, Michael Barry1,2, Roisin Adams1,2.   

Abstract

SARS-CoV-2 continues to widely circulate in populations globally. Underdetection is acknowledged and is problematic when attempting to capture the true prevalence. Seroprevalence studies, where blood samples from a population sample are tested for SARS-CoV-2 antibodies that react to the SARS-CoV-2 virus, are a common method for estimating the proportion of people previously infected with the virus in a given population. However, obtaining reliable estimates from seroprevalence studies is challenging for a number of reasons, and the uncertainty in the results is often overlooked by scientists, policy makers, and the media. This paper reviews the methodological issues that arise in designing these studies, and the main sources of uncertainty that affect the results. We discuss the choice of study population, recruitment of subjects, uncertainty surrounding the accuracy of antibody tests, and the relationship between antibodies and infection over time. Understanding these issues can help the reader to interpret and critically evaluate the results of seroprevalence studies.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; antibody testing; coronavirus; seroprevalence

Mesh:

Substances:

Year:  2021        PMID: 33925518     DOI: 10.3390/ijerph18094640

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


  47 in total

Review 1.  Statistical inference by confidence intervals: issues of interpretation and utilization.

Authors:  J Sim; N Reid
Journal:  Phys Ther       Date:  1999-02

2.  Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.

Authors:  Quan-Xin Long; Xiao-Jun Tang; Qiu-Lin Shi; Qin Li; Hai-Jun Deng; Jun Yuan; Jie-Li Hu; Wei Xu; Yong Zhang; Fa-Jin Lv; Kun Su; Fan Zhang; Jiang Gong; Bo Wu; Xia-Mao Liu; Jin-Jing Li; Jing-Fu Qiu; Juan Chen; Ai-Long Huang
Journal:  Nat Med       Date:  2020-06-18       Impact factor: 53.440

3.  Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020.

Authors:  Fiona P Havers; Carrie Reed; Travis Lim; Joel M Montgomery; John D Klena; Aron J Hall; Alicia M Fry; Deborah L Cannon; Cheng-Feng Chiang; Aridth Gibbons; Inna Krapiunaya; Maria Morales-Betoulle; Katherine Roguski; Mohammad Ata Ur Rasheed; Brandi Freeman; Sandra Lester; Lisa Mills; Darin S Carroll; S Michele Owen; Jeffrey A Johnson; Vera Semenova; Carina Blackmore; Debra Blog; Shua J Chai; Angela Dunn; Julie Hand; Seema Jain; Scott Lindquist; Ruth Lynfield; Scott Pritchard; Theresa Sokol; Lynn Sosa; George Turabelidze; Sharon M Watkins; John Wiesman; Randall W Williams; Stephanie Yendell; Jarad Schiffer; Natalie J Thornburg
Journal:  JAMA Intern Med       Date:  2020-07-21       Impact factor: 21.873

4.  Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York.

Authors:  Eli S Rosenberg; James M Tesoriero; Elizabeth M Rosenthal; Rakkoo Chung; Meredith A Barranco; Linda M Styer; Monica M Parker; Shu-Yin John Leung; Johanne E Morne; Danielle Greene; David R Holtgrave; Dina Hoefer; Jessica Kumar; Tomoko Udo; Brad Hutton; Howard A Zucker
Journal:  Ann Epidemiol       Date:  2020-06-17       Impact factor: 3.797

5.  Asymptotic estimates of SARS-CoV-2 infection counts and their sensitivity to stochastic perturbation.

Authors:  Davide Faranda; Isaac Pérez Castillo; Oliver Hulme; Aglaé Jezequel; Jeroen S W Lamb; Yuzuru Sato; Erica L Thompson
Journal:  Chaos       Date:  2020-05       Impact factor: 3.642

Review 6.  Infection fatality rate of COVID-19 inferred from seroprevalence data.

Authors:  John P A Ioannidis
Journal:  Bull World Health Organ       Date:  2020-10-14       Impact factor: 9.408

7.  The many estimates of the COVID-19 case fatality rate.

Authors:  Dimple D Rajgor; Meng Har Lee; Sophia Archuleta; Natasha Bagdasarian; Swee Chye Quek
Journal:  Lancet Infect Dis       Date:  2020-03-27       Impact factor: 25.071

8.  Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials.

Authors:  Devan V Mehrotra; Holly E Janes; Thomas R Fleming; Paula W Annunziato; Kathleen M Neuzil; Lindsay N Carpp; David Benkeser; Elizabeth R Brown; Marco Carone; Iksung Cho; Deborah Donnell; Michael P Fay; Youyi Fong; Shu Han; Ian Hirsch; Ying Huang; Yunda Huang; Ollivier Hyrien; Michal Juraska; Alex Luedtke; Martha Nason; An Vandebosch; Honghong Zhou; Myron S Cohen; Lawrence Corey; Jonathan Hartzel; Dean Follmann; Peter B Gilbert
Journal:  Ann Intern Med       Date:  2020-10-22       Impact factor: 25.391

9.  Genomic evidence for reinfection with SARS-CoV-2: a case study.

Authors:  Richard L Tillett; Joel R Sevinsky; Paul D Hartley; Heather Kerwin; Natalie Crawford; Andrew Gorzalski; Chris Laverdure; Subhash C Verma; Cyprian C Rossetto; David Jackson; Megan J Farrell; Stephanie Van Hooser; Mark Pandori
Journal:  Lancet Infect Dis       Date:  2020-10-12       Impact factor: 25.071

10.  Preexisting and de novo humoral immunity to SARS-CoV-2 in humans.

Authors:  Kevin W Ng; Nikhil Faulkner; Georgina H Cornish; Annachiara Rosa; Ruth Harvey; Saira Hussain; Rachel Ulferts; Christopher Earl; Antoni G Wrobel; Donald J Benton; Chloe Roustan; William Bolland; Rachael Thompson; Ana Agua-Doce; Philip Hobson; Judith Heaney; Hannah Rickman; Stavroula Paraskevopoulou; Catherine F Houlihan; Kirsty Thomson; Emilie Sanchez; Gee Yen Shin; Moira J Spyer; Dhira Joshi; Nicola O'Reilly; Philip A Walker; Svend Kjaer; Andrew Riddell; Catherine Moore; Bethany R Jebson; Meredyth Wilkinson; Lucy R Marshall; Elizabeth C Rosser; Anna Radziszewska; Hannah Peckham; Coziana Ciurtin; Lucy R Wedderburn; Rupert Beale; Charles Swanton; Sonia Gandhi; Brigitta Stockinger; John McCauley; Steve J Gamblin; Laura E McCoy; Peter Cherepanov; Eleni Nastouli; George Kassiotis
Journal:  Science       Date:  2020-11-06       Impact factor: 47.728

View more
  8 in total

1.  Seroprevalence Survey of Anti-SARS-CoV-2 Antibodies in a Population of Emilia-Romagna Region, Northern Italy.

Authors:  Stefania Paduano; Pasquale Galante; Nausicaa Berselli; Luca Ugolotti; Alberto Modenese; Alessandro Poggi; Marcella Malavolti; Sara Turchi; Isabella Marchesi; Roberto Vivoli; Paola Perlini; Rossana Bellucci; Fabriziomaria Gobba; Marco Vinceti; Tommaso Filippini; Annalisa Bargellini
Journal:  Int J Environ Res Public Health       Date:  2022-06-27       Impact factor: 4.614

Review 2.  SARS-CoV-2 seroprevalence around the world: an updated systematic review and meta-analysis.

Authors:  Mobin Azami; Yousef Moradi; Asra Moradkhani; Abbas Aghaei
Journal:  Eur J Med Res       Date:  2022-06-02       Impact factor: 4.981

3.  The burden of SARS-CoV-2 among healthcare workers across 16 hospitals of Kashmir, India-A seroepidemiological study.

Authors:  Inaamul Haq; Mariya Amin Qurieshi; Muhammad Salim Khan; Sabhiya Majid; Arif Akbar Bhat; Rafiya Kousar; Iqra Nisar Chowdri; Tanzeela Bashir Qazi; Abdul Aziz Lone; Iram Sabah; Misbah Ferooz Kawoosa; Shahroz Nabi; Ishtiyaq Ahmad Sumji; Shifana Ayoub; Mehvish Afzal Khan; Anjum Asma; Shaista Ismail
Journal:  PLoS One       Date:  2021-11-19       Impact factor: 3.240

4.  Testing Denmark: a Danish Nationwide Surveillance Study of COVID-19.

Authors:  Kamille Fogh; Jarl E Strange; Bibi F S S Scharff; Alexandra R R Eriksen; Rasmus B Hasselbalch; Henning Bundgaard; Susanne D Nielsen; Charlotte S Jørgensen; Christian Erikstrup; Jakob Norsk; Pernille Brok Nielsen; Jonas H Kristensen; Lars Østergaard; Svend Ellermann-Eriksen; Berit Andersen; Henrik Nielsen; Isik S Johansen; Lothar Wiese; Lone Simonsen; Thea K Fischer; Fredrik Folke; Freddy Lippert; Sisse R Ostrowski; Thomas Benfield; Kåre Mølbak; Steen Ethelberg; Anders Koch; Ute Wolff Sönksen; Anne-Marie Vangsted; Tyra Grove Krause; Anders Fomsgaard; Henrik Ullum; Robert Skov; Kasper Iversen
Journal:  Microbiol Spectr       Date:  2021-12-15

5.  Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic.

Authors:  Gro Tunheim; Gunnar Øyvind Isaksson Rø; Trung Tran; Anne-Marte Bakken Kran; Jan Terje Andersen; Eline Benno Vaage; Anette Kolderup; John Torgils Vaage; Fridtjof Lund-Johansen; Olav Hungnes
Journal:  Influenza Other Respir Viruses       Date:  2021-11-09       Impact factor: 4.380

Review 6.  Investigating SARS-CoV-2 Susceptibility in Animal Species: A Scoping Review.

Authors:  Connor Rutherford; Pratap Kafle; Catherine Soos; Tasha Epp; Lori Bradford; Emily Jenkins
Journal:  Environ Health Insights       Date:  2022-06-28

7.  Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.

Authors:  Gro Tunheim; Gunnar Øyvind Isaksson Rø; Adity Chopra; Audun Aase; Anne-Marte Bakken Kran; John Torgils Vaage; Fridtjof Lund-Johansen; Olav Hungnes
Journal:  Influenza Other Respir Viruses       Date:  2022-06-30       Impact factor: 5.606

8.  Viral transport media for COVID-19 testing.

Authors:  Matthew J Mears; Michael J Wallace; Jacob S Yount; Lorri A Fowler; Penny S Jones; Peter J Mohler; Loren E Wold
Journal:  MethodsX       Date:  2021-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.